Amylyx Pharmaceuticals (AMLX) Assets Average (2022 - 2026)

Amylyx Pharmaceuticals' Assets Average history runs 5 years deep, the most recent figure standing at $313.1 million for Q1 2026.

• On a quarterly basis, Assets Average rose 51.52% year-over-year to $313.1 million in Q1 2026; TTM through Mar 2026 was $313.1 million, a 51.52% increase from a year earlier, with the FY2025 full-year figure at $263.1 million, down 25.99% from the prior year.
• Assets Average eased to $313.1 million in Q1 2026 per AMLX's latest filing, from $347.7 million in the prior quarter.
• Across five years, Assets Average topped out at $492.0 million in Q4 2023 and bottomed at $190.0 million in Q1 2022.
• The 5-year median for Assets Average is $291.4 million (2024), against an average of $318.9 million.
• Across the five-year window, Assets Average soared 126.26% in 2023 and slumped 55.79% in 2025, its largest moves.
• Year by year, Assets Average stood at $286.4 million in 2022, then surged by 71.77% to $492.0 million in 2023, then plunged by 54.84% to $222.2 million in 2024, then jumped by 56.5% to $347.7 million in 2025, then decreased by 9.94% to $313.1 million in 2026.
• Per Business Quant, the three latest AMLX Assets Average figures stand at $313.1 million (Q1 2026), $347.7 million (Q4 2025), and $278.7 million (Q3 2025).